International Roadshow: New Advances in Endocrinology and Metabolic Diseases

Dear Readers,

Currently, there is a myriad of new developments in the field of endocrinology. In particular, significant strides have been made in the development of poly-agonists for the treatment of type 2 diabetes and obesity [1] [2]. Poly-agonists represent a novel therapeutic approach by combining multiple actions within a single molecule, targeting multiple receptors simultaneously to achieve enhanced efficacy. These innovative compounds aim to address the complex interplay of hormonal pathways involved in glucose regulation and metabolism, offering potential breakthroughs in the management of diabetes and obesity.

Publication History

Article published online:
11 April 2024

• References

• 1 Nauck MA, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 2021; 46: 101102
• 2 Tschöp MH, Friedman JM. Seeking satiety: from signals to solutions. Sci Transl Med 2023; 15: eadh4453
• 3 Oikonomakos IT, Anjana RM, Mohan V. et al. Recent advances in artificial intelligence-assisted endocrinology and diabetes. Explor Endocri Metab Dis 2023; 1: 16-26
• 4 Bornstein SR, Ludwig B, Steenblock C. Progress in islet transplantation is more important than ever. Nat Rev Endocrinol 2022; 18: 389-390
• 5 Hartmann-Boyce J, Rees K, Onakpoya I. et al. An update to the overview of reviews: risks of and from SARS-COV-2 infection and COVID-19 in people with diabetes. Diabetes Care 2023; 46: e215-e216
• 6 Steenblock C, Toepfner N, Beuschlein F. et al. SARS-CoV-2 infection and its effects on the endocrine system. Best Pract Res Clin Endocrinol Metab 2023; 37: 101761
• 7 Perakakis N, Harb H, Hale BG. et al. Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases. Lancet Diabetes Endocrinol 2023; 11: 675-693
• 8 Taneera J, Saber-Ayad MM. Preservation of β-cells as a therapeutic strategy for diabetes. Horm Metab Res 2024; 56: 261-271
• 9 Taneera J, Mahgoub E, Qannita R. et al. β-thalassemia and diabetes mellitus: current state and future directions. Horm Metab Res 2024; 56: 272-278
• 10 Schepp F, Schubert U, Schmid J. et al. Mechanistic insights into ferroptotic cell death in pancreatic islets. Horm Metab Res 2024; 56: 279-285
• 11 Schubert U, Lehmann S, Schmid J. et al. The adrenal gland and pancreatic islets - a beneficial endocrine alliance. Horm Metab Res 2024; 56: 286-293
• 12 Toktogulova N, Breidert M, Eschbach J. et al. Energy metabolism in residents in the low- and moderate altitude regions of central Asia with MAFLD and type 2 diabetes mellitus. Horm Metab Res 2024; 56: 294-299
• 13 Gruber S, Stasi E, Boan Pion A. et al. Unawareness of primary aldosteronism as a common cause of hypokalemia – insights from the IPAHK+ trial (incidence of primary aldosteronism in patients with hypokalemia). Horm Metab Res 2024; 56: 300-307
• 14 Steenblock C, Richter S, Lindemann D. et al. Marine sponge-derived secondary metabolites modulate SARSCoV-2 entry mechanisms. Horm Metab Res 2024; 56: 309-317
• 15 Bornstein SR, Cozma D, Kamel M. et al. Long-COVID, metabolic and endocrine disease. Horm Metab Res 2022; 54: 562-566
• 16 Kronstein-Wiedemann R, Tausche K, Kolditz M. et al. Long-COVID is associated with impaired red blood cell function. Horm Metab Res 2024; 56: 318-323